Abstract Autoinflammatory diseases are a group of diseases characterized by inflammatory attacks.
Autoinflammatory diseases are characterized by apparently unprovoked generalized inflammation in the absence of infection or high titer autoantibodies [39] . The betterdefined diseases within this group are monogenic disorders, especially the hereditary periodic fever syndromes. These genetic diseases have provided insight in innate immune mechanisms and in the pathogenesis of autoinflammatory diseases in general (see Table 1 ). The common pathophysiologic feature for many of these disorders appears to be excessive interleukin-(IL-) 1 signaling [39] .
The spectrum of autoinflammatory diseases ranges from monogenic diseases such as FMF to multifactorial diseases such as systemic juvenile idiopathic arthritis (JIA) and Behçet syndrome [41] .
Most monogenic autoinflammatory diseases are rare and have been identified only recently, the exception being familial Mediterranean fever (FMF) which has been recognized long ago and is rather frequent in certain populations. Our knowledge of autoinflammatory diseases, although expanding rapidly, is still very limited. Our understanding of pathogenesis is vague, but more importantly, we cannot answer the questions that trouble our patients: what is the best treatment and what will the prognosis be? Since most hereditary autoinflammatory diseases are very rare, a multicenter approach is needed to collect the necessary data. Even a wellstudied disease like FMF, which has a prevalence of 1/500-1/ 1,000 in certain Mediterranean countries, appears to behave differently when affected patients live in Northern regions. Therefore, we still need to study its clinical presentation and course and adapt diagnostic criteria that had been developed in "endemic" countries.
The diagnosis of most hereditary autoinflammatory diseases is made by identifying pathogenic mutations in the relevant genes. However, genetic testing is expensive. Moreover, clinically, these diseases share many symptoms. Therefore, we need international evidence-based criteria to make a (presumptive) clinical diagnosis and to guide genetic analysis, based on the diagnostic algorithms [18] . These algorithms have to be applied and validated in different populations and ethnicities. Moreover, many patients with typical features of an autoinflammatory disease still lack a precise molecular characterization.
In the present article, we would like to review the state of the art of the current knowledge on the diagnosis and treatment of these conditions and underline the possible future perspectives for an integrated approach to these rare conditions.
The diagnostic approach to autoinflammatory diseases in children Familial Mediterranean fever (FMF, MIM249100) FMF is a monogenic autoinflammatory disease associated with mutations in a gene called MEFV (from MEditerranean FeVer) gene [53, 54] . The mutations in the MEFV gene result in excess interleukin-1 (IL-1) production [6, 7] . This results in clinical attacks of inflammation in the form of fever and serositis in the form of peritoneal, pleural, or synovial inflammation along with increased acute phase reactants. FMF is an autosomal recessive disease.
Clinically, recurrent attacks last 1/2-3 days on average and resolve spontaneously. Fever sometimes may be the only manifestation of an attack. Frequency of the attacks varies from once a week to once every 3-6 months. Attacks can be triggered by different factors such as physical and emotional stress [45] . The frequency of the cardinal signs and symptoms of FMF are fever (92.5%), peritonitis (93.7%), arthritis (47.4%), pleurisy (31.2%), amyloidosis (12.9%), and non-amyloid glomerular disease (0.8%) [56] . In a multicenter study from Turkey, representing the largest series of FMF, the mean age of onset and diagnosis were 9.6±8.6 years and 16.4±11.6 years, respectively [56] .
FMF is the only periodic fever disease with wellestablished classification/diagnostic criteria: Livneh et al. from Israel have defined diagnostic criteria in adult patients: According to these criteria, there are major and minor criteria as well as supportive criteria. The four major criteria include the typical attacks (≥3 of the same type; rectal temperature ≥38°C; 12-72 h) with peritonitis, pleuritis, monoarthritis (hip, knee, ankle), and fever alone. Minor criteria are defined as incomplete attacks, exertional leg pain, and favorable response to colchicine [36] .
Recently, we have attempted to define criteria for childhood as well. The criteria below reach a good sensitivity and specificity in Turkey [59] .
According to these criteria, the presence of at least two of the following criteria are specific for FMFclassification: ▪ Fever (6-72 h, ≥3 attacks), ▪ Abdominal pain (6-72 h, ≥3 attacks), ▪ Chest pain (6-72 h, ≥3 attacks, unilateral), ▪ Arthritis (6-72 h, ≥3 attacks, monoarthritis), ▪ Exertional leg pain and ▪ Family history of FMF However, none of these criteria have been validated in FMF patients residing in other countries of in FMF patients of different ethnic origin.
Other monogenic periodic fever (autoinflammatory) diseases
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS, MIM142680)
Mutations on chromosome 12 in TNFRSF1A, the gene encoding the 55-kDa receptor for TNF, have been associated with this autosomal dominantly inherited disease [40] .
TRAPS is now known to be prevalent in diverse populations. Prolonged fever attacks (often >1 week) associated with abdominal pain, myalgia, arthritis, rash, and pleuritis are characteristic of TRAPS. The myalgia and rash typically migrate. Periorbital edema and painful fasciitis are also rather characteristics [9, 27] . So far, no validated diagnostic criteria are available in literature.
Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS, MIM260920) HIDS is an autosomal recessively inherited periodic fever syndrome caused by mutations in the gene MVK, which codes for the enzyme mevalonate kinase [11, 26] .
Most patients have attacks from the first year of life [15] . Attacks last a few days, during which a range of clinical features may be present: 87% lymphadenopathy, 85% abdominal pain, 83% arthralgia, 71% diarrhea, 71% vomiting, 68% skin lesions, and 63% headache [57] .
No validated diagnostic criteria are available in literature. However, Van der Hilst et al. [57] have defined clinical guidelines for when to consider testing in their population: They require fever episodes of 3-7 days plus one or more of the following:
-Sibling with genetically confirmed HIDS -Elevated serum IgD -First attack after childhood vaccination -Three or more during attacks: lymphadenopathy, abdominal pain, vomiting, or diarrhea -Arthralgia -Ulcers and skin lesions Cryopyrin-associated periodic fever syndromes (CAPS)
Cryopyrinopathies, or cryopyrin-associated periodic syndromes (CAPS), are a group of autoinflammatory diseases caused by mutations in the gene NLRP3, coding for cryopyrin [14, 23] . These include familial cold autoinflammatory syndrome (FCAS, MIM120100), MuckleWells syndrome (MWS, MIM191900), neonatal-onset multisystem inflammatory disease [NOMID, also known as chronic infantile neurologic cutaneous articular (CINCA) syndrome, MIM607115] [44] . All are inherited in an autosomal dominant fashion.
In FCAS, patients experience cold induced episodes of inflammation, characterized by fever, chills, urticaria, joint symptoms, sometimes accompanied by conjunctivitis, that last 6-48 h. Long-term outcome is usually favorable.
In MWS besides fever, urticarial rash, and arthritis, there is hearing loss and eye findings of conjunctivitis, episcleritis, and optic disc edema. Amyloidosis may develop in one fourth of the patients.
NOMID (or CINCA) displays a more chronic clinical inflammation. Characteristic features are continuous rash, lymphadenopathy, mental retardation, ophthalmological findings, abnormal bony overgrowth of the knees, chronic meningitis, a variety of CNS findings, and hearing loss [44, 47] . Mortality is high in untreated patients.
The diagnosis is largely performed on the clinical ground and no validation of diagnostic criteria has been developed so far.
Cold-induced periodic fever associated to NLRP12
Only three families with this rare disorder have been reported so far [4, 31] . Affected patients may develop episodes of arthralgia-myalgia and urticarial rash variably associated with fever. As in FCAS, cold exposure represents the typical trigger for the development of the clinical manifestations. Sensineuronal hearing loss has also been reported in some patients [31] .
Pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome (PAPA, MIM604416)
This autosomal dominant disease is caused by mutations in proline serine threonine phosphatase-interacting protein [PSTPIP1, or CD2-binding protein 1 (CD2BP1)] [35] , also interacting with pyrin [49] . It is very rare.
The characteristic lesions are numerous dermatologic manifestations including cystic acne, expanding purulent ulcerating lesions (pyoderma gangrenosum), and sterile abscesses at injection sites. PAPA syndrome is also characterized by early destruction of the joints by recurrent effusions [35] .
Early-onset sarcoidosis (EOS) (sporadic granulomatous arthritis) and Blau's syndrome (familial granulomatous arthritis)
Mutations of NACHT domain of the CARD15 (NOD2) gene have been shown in 50% of Blau and 90% of EOS patients [42] . CARD15 serves as an intracellular sensor of bacteria and is another member of the inflammatory pathway leading to the activation of the inflammatory signaling cascade triggering NF-kappaB [42] .
Blau syndrome is an autosomal dominant syndrome characterized by synovitis, uveitis and rash. Some authors accept that Blau's syndrome and early-onset sarcoidosis are the same disease: there is an inherited mutation in Blau's and a de novo mutation in EOS (as above) [42] .
Deficiency of the interleukin-1-receptor antagonist (DIRA)
DIRA is a recently identified autosomal recessive autoinflammatory syndrome, due to the deficiency of the interleukin-1-receptor antagonist, which begins around birth with multifocal osteomyelitis, periostitis, and pustulosis [1] . Persistent elevation of acute phase reactants (ESR and CRP) is observed since birth. The skin manifestations range from groupings of small pustules to a generalized pustulosis. The bone manifestations include osteolytic lesion with a sclerotic rim, epiphyseal overgrowth of multiple distal and proximal long bones, widening of ribs and clavicles, heterotopic ossification or periosteal cloaking of the proximal femoral metaphysic, and periosteal elevation of the diaphysis. Fever is not prominent. The patients showed a dramatic response to the substitutive treatment with recombinant IL-1-receptor antagonist (anakinra) [1] .
The multifactorial autoinflammatory diseases
A number of multifactorial inflammatory diseases present clinical similarities with inherited autoinflammatory diseases and are thought to be mainly autoinflammatory in nature [39] . Some of them display a clear clinical overlap with the known inherited diseases and are therefore considered in the differential diagnosis.
Chronic recurrent multifocal osteomyelitis (CRMO)
Clinically, CRMO is characterized by recurring attacks of fever and bone pain of osteomyelitis. The osteomyelitis may recur months or years later [18] . Diagnostic criteria have been recently proposed [30] .
Although CRMO has no clear genetic etiology, it may share pathogenetic mechanisms with rare monogenic disorders, like DIRA and another rare disease, called Majeed syndrome [37] . All three are characterized by similar sterile osteolytic bone lesions.
Behçet disease
Behçet disease is not a monogenic disease. Genome-wide analysis for the disease has identified linkage with the MHC class-1, IL-10, and IL-23R-IL-12R genes [58] . Behçet disease is an inflammatory disease characterized by exacerbations and remissions. In Behçet disease, the inflammation displays itself as mucocutaneous disease and vasculitis. Eye disease and joint inflammation are very common [46] .
Classification criteria have been suggested for adults in 1990 [28] . These criteria require the presence of recurrent oral ulcers and the presence of at least two of the following: genital ulcers, eye involvement (often panuveitis), skin lesions, and a positive pathergy test (1) . Pathergy test is defined as a reaction for the specific skin test at 48-72 h. However, in children, the appearance of the typical clinical manifestations may take several years, thus diagnostic criteria for children are currently under elaboration [33] .
PFAPA syndrome
The periodic fever adenitis pharyngitis aphtosis (PFAPA) syndrome is a disease of early childhood. It is not inherited in a Mendelian fashion. As the name suggests, the patients experience fever attacks which are accompanied by aphtous stomatitis (often exudative), pharyngitis, and cervical adenopathy [22] . Attacks tend to come at regular intervals every 2-6 weeks.
The classical diagnostic criteria developed by Marshall [38] and modified by Thomas et al. [55] are still widely used among pediatricians: However, recent evidences have shown that the specificity of the above criteria is quite low, and that there is considerable overlap with other monogenic periodic syndromes [16] . Work on a new set of criteria is ongoing.
State of the art: management of autoinflammatory diseases
There is limited evidence to guide the management of autoinflammatory diseases. With a few notable exceptions, publications on pharmacotherapy have been limited to case reports. There are no evidence-based guidelines on other aspects of care, such as monitoring for complications. Therefore, research into treatment and care for affected individuals is needed. Even if evidence cannot be obtained, guidelines may be useful.
FMF is the best studied of the autoinflammatory diseases. Management has been systematically reviewed [32] . Colchicine is effective in the prevention of both fever attacks and amyloidosis. The level of evidence in children is weaker than that in adults as is the evidence for optimal dosing. Colchicine dosage in children is based on age. The starting dose for patients <5 years is 0.5 mg/day, between 5 and 10 years of age 1 mg, and >10 years of age 1.5 mg/day in divided doses. Patients who fail to respond to doses up to 2 mg/day or who do not tolerate colchicine have been reported to achieve complete remission with interleukin-1 blockade (anakinra) [2] .
In TRAPS, there is no evidence-based therapy. Disease activity is extremely variable. Hence, inflammation may sometimes be controlled with NSAIDs or glucocorticosteroids, but in severely affected patients these may fail. Etanercept appeared effective in small case series [13] , but antibodies against TNFα such as infliximab appear to worsen disease [29] . Anakinra has been shown to be highly effective in preliminary small studies [17, 50] . Studies with newer anti IL-1β agents are on the way.
Mevalonate kinase deficiency has been treated with many different drugs, but only two have been studied prospectively: thalidomide (which was ineffective) [12] and simvastatin (which showed a very modest effect at best) [51] . Several case reports suggest a favorable effect of etanercept [52] or anakinra [3] , but in a retrospective survey neither drug appeared universally effective [57] , emphasizing the need for prospective studies.
Cryopyrin-associated periodic syndromes (CAPS) have been shown to be universally sensitive to interleukin-1 blockade. The first drug used was the IL-1-receptor antagonist, anakinra [20, 21, 24] . Anakinra has to be injected subcutaneously every day. The IL-1receptor-Fcγ1 fusion protein rilonacept has been shown to be effective when injected weekly in adult patients with CAPS [25] . The human monoclonal antibody against IL-1β, canakinumab was highly effective in a prospective randomized controlled study involving both adult and pediatric patients. Over 95% of patients achieved complete remission within 4 weeks of treatment [34] . Canakinumab could be dosed at 6-to 8-week intervals. Although all available interleukin-1 antagonists appear effective in CAPS, it is impossible to tell which one is superior.
PAPA syndrome has been treated with local and systemic corticosteroids, etanercept [8] and anakinra [10] , but beyond case reports there is no evidence to guide management.
The management of Blau syndrome has not been well studied either. Corticosteroids, immunosuppressive agents, anti-TNF antibodies [48] , and, more recently, thalidomide have been employed [60] .
In CRMO, NSAIDs are the first line of treatment and effectively control pain in the vast majority of patients [19] . Corticosteroids and immunosuppressive drugs are of limited benefit. Recently, a case series suggested beneficial effect of aminobisphosphonates, but this observation needs independent confirmation [43] . In PFAPA syndrome, attacks are generally treated with oral glucocorticoids. Several studies have addressed the value of tonsillectomy in the prevention of recurrent attacks including two randomized controlled trials. In a systematic review, tonsillectomy appeared superior over conservative management [5] , although some referral bias cannot be excluded as all patients were recruited by otolaryngologists.
A glance to the future: an international network for the study of autoinflammatory diseases (the Eurofever Project)
Since 2008, the Pediatric Rheumatology European Society has promoted a project specifically aimed to the establishment of a permanent network for the study of autoinflammatory diseases in childhood. The Eurofever Project is supported by the Executive Agency for Health and Consumers (EAHC, Project No. 2007332).
The project general aims are to (1) promote awareness among pediatricians and pediatric rheumatologists to enhance early recognition of these diseases, (2) provide proper information to families affected by these conditions, and (3) increase the knowledge on the clinical presentation, response to treatment, and complications of these rare disorders.
The major practical aim of the project is to set up an international web-based registry on autoinflammatory diseases.
The primary goal of the Registry is to collect information on the clinical presentation, outcome, and response to treatment of patients affected by the major autoinflammatory diseases. Moreover, the registry also aims (1) to provide clinical classification criteria for the autoinflammatory diseases lacking a precise genetic characterization; (2) to support the development of guidelines for genetic testing for each of the known autoinflammatory loci; (3) to create a permanent network of centers dealing with patients affected by autoinflammatory diseases for future clinical, pathogenic, genetic, and therapeutic studies; (4) to identify informative families or clusters of genetically negative patients for future genetic studies; and (5) to establish baseline cohorts for future outcome studies.
The Eurofever Project has created a single registry for the following diseases: FMF, CAPS, TRAPS, HIDS, Blau's syndrome, CRMO, Behcet's disease, PAPA syndrome, DIRA, and NALP-12 related. Separate registries for some diseases had been available. The advantage of the single EUROFEVER registry is the ability to compare the clinical manifestations occurring in different diseases for the development of clinical criteria to support a diagnosis and guide genetic testing, periodic fever, PFAPA, and undefined periodic fevers.
Thanks to a functional collaboration with already ongoing initiatives in this field, namely The Paediatric Rheumatology International Trials Organization (PRINTO, http://www. printo.it), EuroTRAPS (FP7 project n. HEALTH-F2-2008-200923), the HyperIgD registry (http://hids.net), Infevers (http://fmf.igh.cnrs.fr/ISSAID/infevers/), the ESID registry (http://www.esid.org), and the German registry for autoinflammatory diseases (http://www.aid-register.uk-essen.de), the Eurofever registry is able to reach a large number of centers involved in the management of these conditions in both children and adults; centers that would otherwise not be linked.
A second aim of the project is to provide information on autoinflammatory diseases to families and general pediatricians. Informative web pages in different languages are now available at http://www.printo.it/eurofever.
A third aim of the project is to analyze the efficacy of different therapeutic approaches used in patients with autoinflammatory diseases. Thanks to the registry, we will be able to perform a retrospective analysis of current evidence on treatment practice. These data will guide future therapeutic trials. The Eurofever Project promises to bring together centers that care for enough patients to participate in such prospective multicenter trials.
The outcome measure in therapeutic trials will be disease activity. However, validated indices of disease activity are lacking. Elaboration and validation of these activity parameters represent a further aim of the Project. This part of the project was made in close collaboration with a parallel initiative funded by the French government (AIDAI, Auto-inflammatory Diseases Activity Index) and with the Eurotraps project.
In summary, all hereditary autoinflammatory diseases except FMF are very rare. There are several relevant common unanswered questions: what are the clinical criteria defining these disorders? What are the criteria to proceed to specific DNA tests? Which therapies in current use appear most promising? What is the pathophysiology of these disorders? And can we identify novel autoinflammatory syndromes? The Eurofever Project proposes an integrated and collaborative approach to facilitate and support the research in this fascinating field in the next decade.
